| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9261659 | Autoimmunity Reviews | 2005 | 6 Pages |
Abstract
This article reviews the role of CD20 antigen in B cell function and the effectiveness and limits of passive immunotherapy with anti-CD20 monoclonal antibody (Rituximab) in the treatment of autoimmune (or immune-mediated) diseases. Active immunotherapy is a more feasible way to control these chronic diseases. A peptide that mimics the CD20 epitope recognized by Rituximab is employed to stimulate the host immune response against CD20.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Federico Perosa, Elvira Favoino, Maria Antonietta Caragnano, Marcella Prete, Franco Dammacco,